Abstract
Resveratrol (Rsv) (3,5,4'-trihydroxy-trans-stilbene), is a polyphenol molecule that was 77 identified from the dried roots of Polygonum cuspidatum, a plant used in traditional 78
Chinese and Japanese medicine 1 . Resveratrol has been classified as a phytoalexin as 79 it is synthesized in spermatophytes in response to injury, UV irradiation and fungal 80 attack 2 . It is naturally found in a wide variety of plant species, vegetables, fruits and 81 food products such as peanuts, grape skin, plums or red wine 2 .
82
Resveratrol offers pleiotropic health beneficial effects, including antioxidant and anti-83 aging effects 3 , cardioprotective 4 , anticancer 1 , neuroprotective 5 and HIV/AIDS 84 activities 6 . 85
In the lasts years, it has been demonstrated the preventive effect of resveratrol against 86 diabetes. Resveratrol would normalize hyperglycaemia and, in animals with 87 hyperinsulinemia, it would reduce blood insulin 7 . Similarly, resveratrol was reported to 88 reduce body weight and adiposity in obese recipients 8 . These actions would involve 89 the activation of sirtuin 1 (SIRT1) that inhibits inflammatory pathways in macrophages 90 and modulates insulin sensitivity 9 . Furthermore, different studies have shown that 91 resveratrol is capable of inhibiting lipopolysaccharide (LPS) induced cytokine 92 production 10 . This effect, via modulation of NF-κB, would decrease the production and 93 gene expression of IL1 and TNF-α, important endogenous pyrogens 11 . 94
In spite of these potential health benefits, the use of resveratrol is limited due to its high 95
Renal excretion is the major route of elimination of the polyphenol and its derivatives 104 2, 15 . 105
In order to solve these drawbacks different strategies have been pursued including its 106 encapsulation in different oral delivery systems such as, among others, self-nano 107 emulsifying drug delivery systems 16 , solid lipid nanoparticles 17 and polymeric 108 nanoparticles 18 . 109
An alternative approach might be the use of zein nanoparticles. Zein is the major 110 storage protein of maize and comprises aprox. 45-50% of the total protein content in 111 corn 19 . Since zein is a natural protein, it is actually a heterogeneous mixture of 112 different peptides than can be divided in four main fractions: i) α-zein (75-85% of total 113 protein) with two main MW of 21-25 kDa and 10kDa, ii) β-zein (10-15%) of a MW of 114 17-18 kDa, iii) δ-zein, a minor fraction of 10kDa and vi) γ-zein (5-10%) with a MW of 27 115 kDa 19, 20 . Zein is an amphiphilic protein, possessing high percentages of hydrophobic 116 amino acids such as leucine (20%), proline (10%) and alanine (10%) 19, 20 . Due to this 117 amino acid composition, zein is insoluble in water and, thus, the resulting devices (e.g. 118 films, nanoparticles) display an hydrophobic character with interesting properties to 119 control the release of the loaded compound 20, 21 . In addition, as for other nanocarriers 120 from protein origin, they are biodegradable and can accommodate a great variety of 121 compounds in a non-specific way 22 . 122 Therefore, the aim of this work was to prepare, characterize and evaluate a resveratrol 123 nanoparticulate formulation based on zein and to study its oral bioavailability and anti-124 inflammatory effect in a mouse model of induced endotoxic shock. 125 37.5 mg of resveratrol in 5 mL of PEG400 under magnetic stirring. Then 5 mL of 159 purified water were added and the final mixture was agitated in the dark for 10 min. 160
This formulation was named Rsv-sol. 161
The second one was an extemporary suspension of resveratrol in purified water (Rsv-162 susp). Briefly, 37.5 mg of resveratrol were dispersed in 10 mL of purified water under 163 magnetic agitation for 10 min. The size of the resulting suspension was 21.4 ± 9.2 μm. 164
The suspension was used after inspection for absence of aggregates. 165
Characterization of nanoparticles 166
Size, zeta potential and morphology 167
The mean hydrodynamic diameter and the zeta potential of nanoparticles were 168 determined by photon correlation spectroscopy (PCS) and electrophoretic laser 169 Doppler anemometry, respectively, using a Zetamaster analyzer system (Malvern 170 Instruments Ltd., Worcestershire, UK). The diameter of the nanoparticles was 171 determined after dispersion in ultrapure water (1:10) and measured at 25 ºC with a 172 scattering angle of 90 °C. The zeta potential was measured after dispersion of the dried 173 nanoparticles in 1 mM KCl solution. 174
The morphology of the nanoparticles was studied using a field emission scanning 175 electron microscopy (SEM) in a Zeiss DSM940 digital scanning electron microscope 176 (Oberkochen, Germany) coupled with a digital image system (Point Electronic GmBh, 177
Germany). The yield of the process was calculated by gravimetry as described 178 previously 22 . 179
Resveratrol analysis 180
C18 support AJO-7596 precolumn. The mobile phase, pumped at 0.25 mL/min was a 187 mixture of water/methanol/acetic acid in a gradient condition. The column was heated 188 at 40 °C and the injection volume was 10 µL. Under these conditions, the retention time 189
for resveratrol was 22.8±0.5 min. Calibration curves in ethanol 75% were designed 190 over the range of 1-100 µg/mL (R 2 0.999). Under these experimental conditions, the 191 limit of quantitation was calculated to be 200 ng/mL. 192
For analysis, 10 mg nanoparticles were dispersed in 1 mL of water and centrifuged at 193 30,500 g for 20 min. The amount of encapsulated resveratrol was calculated by 194 dissolution of the pellets with 1 mL of ethanol 75%. Each sample was assayed in 195 triplicate and the results were expressed as the amount of resveratrol (µg) per mg of 196
nanoparticles. 197
The encapsulation efficiency (E.E) was calculated as follows: 198
where Rsv-t is the total amount of resveratrol in the formulations and, Rsv-p, the 200 amount of resveratrol quantified in the pellet. 201
In vitro release study 202
Release experiments were conducted under sink conditions at 37°C using simulated 203 gastric (pH 1.2; SGF) and intestinal (pH 6.8; SIF) fluids The contribution of Fickian and non-Fickian release was also evaluated by using the 226 Peppas-Sahling model equation 26 : 227 
[Eq 5] 234
Only one portion of the release profile (Mt/M∞ ≤ 0.6) was used to fit the experimental 235 data to the previous equation. 236
In vivo pharmacokinetic studies in Wistar rats 237

Pharmacokinetic studies 238
Pharmacokinetic studies were performed in male Wistar rats (200-250 g) obtained from 239
Harlan (Barcelona, Spain). Studies were approved by the Ethical Committee for Animal 240
Experimentation of the University of Navarra (protocol number 028-11) in accordance 241 with the European legislation on animal experiments. 242
Prior to the oral administration of the formulations, animals were fasted overnight to 243 avoid interference with the absorption, allowing free access to water. For the 244 pharmacokinetic study, rats were randomly divided into 4 groups of 6 animals each. 245
The three experimental groups were: (i) resveratrol water suspension (Rsv-susp), (ii) 246 resveratrol solution in a PEG400:water mixture (Rsv-sol) and (iii) resveratrol-loaded 247 zein nanoparticles (Rsv-NP-Z). As control, a group of animals was treated 248 intravenously with the PEG400:water 
Determination of resveratrol and resveratrol-3-O-D-glucuronide plasma 257 concentration by HPLC 258
The amount of resveratrol was determined by HPLC-UV following an analytical method 259 previously reported with minor modifications 27 . Analysis were carried out in an Agilent 260 model 1100 series LC and diode-array detector set at 306 nm. Data were analysed in a 261
Chemstation G2171 program (B.01.03). The chromatographic system was equipped 262 with a reversed-phase C18 Kromasil column (250 mm x 2.1 mm; particle size 5 µm) 263 and a Gemini C18 support AJO-7596 precolumn. The mobile phase, pumped at 0.5mL/min, was a mixture of water, methanol and acetic acid (50:45:5 by vol.) under 265 isocratic conditions. The column was thermostatized at 30°C and the injection volume 266 was 30 µL. Under these conditions, the retention times for resveratrol-3-O-D-267 glucuronide and resveratrol were 6.2 ± 0.5 min and 12.6 ± 0.5 min, respectively. 268
For analysis, a 100 µL aliquot of plasma was mixed with 50 µL HCl 0.1 N and 500 µL 269 acetonitrile (for protein precipitation) followed by vigorous shaking. Then, samples were 270 centrifuged at 4000 rpm for 10 min and the obtained supernatants were evaporated 271 under vacuum in a Speed Vac® system (Holbrook, NY) at 25°C for 30 min. Finally, 100 272 µL of a mixture of acetonitrile and water (1:1 by vol.) was added and vigorously stirred 273 in a vortex for 10 min. Then, and prior to the injection, samples were filtered through 274 0.45 µm filter (Thermo scientific, Rockford, IL, USA). 275
For quantification, calibration curves were prepared over the range 2 to 70 µg/mL for 276 the metabolite and 50 to 3,000 ng/mL for resveratrol (R 2 0.99). All the calibration 277 standards were obtained by adding either resveratrol or resveratrol-3-O-D-glucuronide 278 in acetonitrile (500 µL) to 100 µL plasma from non-treated animals. Then, the 279 polyphenol or its metabolite was extracted using the same protocol described above. 280
Under these experimental conditions, the limit of quantification was calculated to be 70 281 ng/mL, for resveratrol, and 4 µg/mL for the metabolite. Linearity, accuracy and 282 precision values during the same day (intra-day assay) at low, medium and high 283 concentrations of both resveratrol and the metabolite were always within the 284 acceptable limits (relative error and coefficient of variation less than 15%). 285
Pharmacokinetic data analysis 286
Resveratrol plasma concentration was plotted against time, and pharmacokinetic 287 analysis was performed using a non-compartmental model with the WinNonlin 5. 
In vitro/In vivo correlation (INVIC) 298
The eventual correlation between in vitro and in vivo results was conducted by plotting 299 a point-to-point between the amount of resveratrol released from nanoparticles vs the 300 fraction of resveratrol absorbed (FRA) calculated from the mean plasma concentration-301 time inputs using the Wagner-Nelson equation 28 : 302
where Ct is the plasma concentration of resveratrol at a time t, k is the elimination rate 304 constant of the polyphenol, AUC 0-t is the area under the resveratrol concentration vs. 305 time curve from 0 to time t, and AUC 0-∞ is the area under the curve from 0 to infinity. 306
Linear regression analysis was applied to the in vitro-in vivo correlation plot and 307 coefficient of determination (R 2 ) was calculated. 308
Anti-inflammatory efficacy study 309
Animal model 310
Four weeks-old (20-22 g) C57BL/6J female mice were purchased from Harlan 311 (Barcelona, Spain) and housed in standard animal facilities (6 animals per cage with 312 free access to food and drinking water). Housing conditions were maintained by 313 controlled temperature and humidity and with 12 h on/off light cycles. Animals were 314 allowed to acclimate for one week before the experiment. 315
In vivo anti-inflammatory studies were evaluated in an endotoxic shock model set up by 316 intraperitoneal (ip) administration of LPS at a dose of 40 µg per mouse 29. Before 317 administration, LPS was dissolved in PBS and vortexed during 30 min to complete 318 homogenization.
On day 1, mice were randomly distributed into four groups. The first group of animals 320 received an oral dose of 15 mg/kg resveratrol daily as oral solution (Rsv-sol) during 7 321 days. The second group of animals received the same posology of polyphenol (15 322 mg/kg resveratrol daily; 7 days) but formulated in zein nanoparticles (Rsv-NP-Z).. As 323 controls, a group of animals received LPS treatment (positive control group) and 324 another one received neither LPS nor resveratrol (negative control group). 325
Twenty-four hours after the last dose of resveratrol (day 8) animals were challenged 326 with 40 μg LPS by ip route. Throughout the study, rectal temperature of mice was 327 measured until 24 h after challenge. Similarly, animals were observed for any clinical 328 signs or symptoms of toxicity daily and after the challenge. The severity of symptoms 329 was scored as follows:: i) (-) absent; ii) (+) weak; iii) (++) moderate; and iv) (+++) 330 strong. Depending on the activity of animals, their mobility was classified as very low, 331 low or normal. 332
In addition, 90 min after challenge, blood samples were collected from the retro-orbital 333 cavity in EDTA-K vials (Microvette® 500K3E, SARSTEDT, Germany), centrifuged at 334 8,000 g for 10 min for sera collection and stored at -20 °C until use. 335
Measurement of plasma TNF-α 336
The concentration of circulating TNF-α in the serum was determined by an enzyme-337 linked immunosorbent assay kit (Quantikine® ELISA Mouse TNF-α, MTA00B, R&D 338 Systems, Minneapolis, USA) according to manufacturer's instructions. 339
Statistical analysis 340
Data are expressed as the mean ± standard deviation (S.D.) of at least three 341 experiments. The non-parametric Kruskall-Wallis followed by Mann-Whitney U-test was 342 used to investigate statistical differences. In all cases, p< 0.05 was considered to be 343 statistically significant. All data processing was performed using Graph Pad® Prism 344 statistical software. 345 Table 1) . Additionally, the resveratrol loading was calculated to be about 80 356 μg/mg nanoparticles, with an encapsulation efficiency close to 82%. 357 Figure 1 shows the morphology and shape of resveratrol-loaded nanoparticles. In all 358
Preparation and characterization of nanoparticles 348
cases, nanoparticles consisted of homogeneous populations of spherical particles with 359 a smooth surface. In addition, the size of nanoparticles as observed by SEM was in line 360
with the values determined by photon correlation spectroscopy ( Table 1) . 361
In vitro release profile 362 Figure 2A represents the release profile of resveratrol from nanoparticles expressed 363 as cumulative percentage of drug released versus time. In all cases, the release of 364 resveratrol from zein-based nanoparticles was found to be independent of the pH 365 conditions. During the first 2 h, under SGF conditions (pH 1.2), about 20% of the 366 loaded resveratrol was released from zein nanoparticles. Then, 6 hours later (during 367 incubation in SIF conditions) the amount released was close to 60% of the total content 368 of resveratrol. After 48 h, all the loaded resveratrol was released from nanoparticles. 369
The release profile of resveratrol from NPs was fitted to different mathematical release 370 ). Figure 2B displays the contribution of both the diffusion and erosion 376 mechanisms on the release of resveratrol from zein nanoparticles. The time at which 377 both mechanisms (diffusion and erosion) contributed in a similar amount to the release 378 of resveratrol was calculated to be 3.5 h. 379 Figure 3A shows the plasma concentration-time profile of a resveratrol solution in 381 PEG-400:water (1:1 by vol.) after the intravenous administration to rats of a single dose 382 of 15 mg/kg. The data were adjusted to a non-compartmental model. The resveratrol 383 plasma concentration decreased rapidly in a biphasic way during the first 8-h post 384 administration. The peak plasma concentration (C max ) of resveratrol was around 15 385 µg/mL, whereas the AUC and half-life (t 1/2 ) were calculated to be 11.4 µg h/mL and 2.0 386 h, respectively. The resveratrol clearance and its volume of distribution were about 0.2 387 L/h and 0.6 L, respectively ( Table 2) . 388 Figure 3B shows the plasma concentration levels of resveratrol when administered 389 orally as a single dose of 15 mg/kg to rats. Interestingly, when resveratrol was 390 formulated as a suspension, no detectable levels of the polyphenol were quantified in 391 plasma. On the other hand, when resveratrol was administered as solution (Rsv-sol), 392 the polyphenol plasma levels displayed an initial maximum concentration (C max ) of 393 around 0.2 µg/mL, 30 min after administration. Then, the plasma levels of resveratrol 394 decreased rapidly and quantifiable levels were only detected during the first 4 h post-395
In vivo pharmacokinetics 380
administration. 396
For resveratrol-loaded in zein nanoparticles (Rsv-NP-Z), the amount of the polyphenol 397 in plasma increased during the first 4 h after administration until reaching a maximum. 398
Then, the resveratrol plasma levels decreased slowly for the following 20 h. Forty-eight 399 hours post-administration, the amount of resveratrol in plasma was very close to the 400 quantitation limit of the analytical technique.the different formulations to rats. The resveratrol AUC values from zein nanoparticle 404 formulations were significantly higher (p< 0.05) than those observed for the polyphenol 405 solution. Similarly, the resveratrol MRT was thirteen-times higher when administered in 406 the form of zein nanoparticles than when solubilized in the PEG400:water oral mixture. 407
Finally, the relative oral bioavailability of resveratrol when incorporated in nanoparticles 408 was calculated to be 50 % using zein nanoparticles. This value was significantly higher 409 than the bioavailability obtained with the PEG400:water solution (2.6 %). 410 Figure 4 shows the plasma concentration versus time profile of the resveratrol main 411 metabolite (resveratrol-O-3-glucuronide) after the single administration of the 412 polyphenol in the formulations tested. Interestingly, the profile of the plasma curves for 413 both resveratrol and its metabolite were similar; however, the metabolite levels were 414 always higher than for the polyphenol. When resveratrol was administered 415 intravenously, the metabolite concentration reached 41.9 µg/mL (C max ) and, then, the 416 metabolite levels decreased sharply. The AUC value was calculated to be 197 µg 417 h/mL. 418
For the solution of resveratrol orally administered, the C max of the metabolite in plasma 419 was found to be 2-times lower (22.1 µg/mL) than when administered by the iv route. In 420 this case, the metabolite was only quantified in plasma during the first 8 h post-421 administration. The AUC value was calculated to be 104 µg h/mL; around half the i.v. 422 solution one. 423
For nanoparticles, the metabolite was quantified during the first 24 hours after 424 administration. In addition, the metabolite AUC data was around 342 µg h/mL for Rsv-425 NP-Z. This value was around three-times higher than with the resveratrol was 426 administered as oral solution or intravenously. 427 Table 3 shows the overall endotoxic symptoms score including the number of animals 444 displaying a temperature 2 ºC lower than the basal temperature, 6 h post-challenge. 445
In vitro-in vivo correlations 428
Positive control animals displayed a low mobility and signs of bristly hair and 446 respiratory distress. On the contrary, animals treated with Rsv-NP-Z displayed an 447 almost normal behaviour and an evident better symptomatology than those animals 448 receiving resveratrol as oral solution, which appeared to be immobile or with a high 449 difficulty to coordinate any simple movement. 450 Figure 6B shows the serum levels of TNF-α measured by ELISA before and 90 min 451 after LPS challenge. Negligible levels of TNF-α were observed before LPS 452 administration. The oral administration of Rsv-NP-Z induced a decrease in the levels of 453 TNF-α with respect to mice pre-treated with resveratrol solution and the positive controlIn the past zein was proposed as material for the preparation of nanoparticles due to its 459 hydrophobic character, degradability, adherence properties and versatile processability 460 19, 20 . However, as zein possesses abundant non-polar amino acids, the dispersability of 461 the resulting nanoparticles in an aqueous media (and, therefore, their potential 462 applications) is a challenge 30 . Recently, the use of citrate and phosphate salts was 463 proposed to minimize this problem 31 . In our case, lysine was added during the 464 preparative process of nanoparticles. In this way, the resulting dry powder of zein 465 nanoparticles was easily redispersed, yielding a homogeneous fine suspension ( Table  466 1) after the addition of water and simple hand agitation. . The release of resveratrol from zein nanoparticles was found to be pH-independent. 472
In fact, this phenomenon would be a combination of both Fickian diffusion and erosion 473 of the nanoparticle matrix (Peppas-Sahlin model). During the first hours of the release 474 process, resveratrol molecules would mainly diffuse from the nanoparticles to the 475 aqueous medium by Fickian diffusion. Later (3.5 h), the release of resveratrol would be 476 mainly due to an erosion and/or relaxation process of the nanoparticle matrix. 477
Interestingly, as a consequence of both phenomena, the amount of resveratrol 478 released (at least during the first 8 h) is constant and approaches to a zero order 479
kinetic. 480
Pharmacokinetic studies were carried out at a single dose of 15 mg/kg, comparable to 481 those used in previous studies 33, 34 . The oral administration of a single dose of 482 resveratrol as an aqueous suspension (Rsv-susp) to rats did not produce quantifiable 483 levels of the polyphenol in plasma (Figure 3B) . For the solution formulation, in aof resveratrol in plasma were detected. These findings are directly related with the 487 extensive metabolism of resveratrol 35 . In fact, when administered orally, resveratrol 488 (due to its lipophilic character) can rapidly enter into the enterocyte by passive diffusion 489
36
; although, it is highly metabolized to glucuronide and sulphate derivatives, which may 490 be secreted back to the intestinal lumen through multidrug resistance protein 2 (MRP2) 491 and BCRP 37, 38 . This extensive biotransformation of resveratrol decreases circulation 492 levels of free resveratrol and facilitates its excretion (in the form of conjugates) by the 493 kidneys via urine 14 . Controversy remains about the physiological activity of metabolites 494 or if they can act as resveratrol prodrugs. There are evidences that, at sufficient 495 concentrations, resveratrol metabolites have biological activity in various tissues 36 . 496
Nevertheless, there are also evidences that these compounds have no effects in some 497 tissues 39 .
498
However, when resveratrol was administered after its encapsulation in zein 499 nanoparticles, sustained and prolonged plasma levels of the polyphenol were observed 500 for at least 24 h ( Figure 3B ) and its relative oral bioavailability was about 50% (Table  501 3), which is about 18-fold higher than the value observed for Rsv-sol (about 2.6%). This 502 increased capability to promote the absorption and bioavailability of resveratrol by 503 using zein nanoparticles would be related with its high hydrophobic character, that 504 would offer a higher stability in vivo, and to the capability of this corn protein to develop 505 mucoadhesive interactions within the gut mucus layer 40 . Thus, this characteristic would 506 provide a longer residence in close contact with the intestinal epithelium and facilitating 507 the establishment of a concentration gradient from the nanoparticulate matrix untill the 508 absorptive membrane. Interestingly, the fraction of resveratrol absorbed from zein 509 nanoparticles correlated well with the percentage of the polyphenol released in vitro 510 (see Figure 5) . 511
In previous studies, it has been reported that the oral bioavailability of resveratrol is 512 almost zero 34, 41 . In order to improve its absorption different strategies have been 513
proposed such as the use of oral absorption enhancers (e.g. Tween 80, cyclodextrins)or the employment of resveratrol derivatives. In this way, Kapetanovic and co-workers 515 have reported an oral bioavailability of resveratrol (formulated as aqueous solution 516 containing methylcellulose and Tween 80) close to 30% after the administration of a 517 single dose of 50 mg/kg in rats. In the same work, the administration of the same 518 resveratrol formulation at a dose of 150 mg/kg produced an oral bioavailability of 19% 519
42
. In another work, resveratrol trimethyl-ether administered orally in a solution 520 formulated with randomly methylated-β-cyclodextrin (15 mg/kg) yielded a bioavailability 521 of about 47%. More recently, the use of nanocarriers has also been proposed. Thus, in 522 mice and using a dose of 50 mg/kg, the oral bioavailability of resveratrol when loaded 523 in either Eudragit or chitosan/lecithin nanoparticles was calculated to be 39 and 61%, 524 respectively 43 . For solid lipid nanoparticles, the oral bioavailability of the polyphenol 525 was found to be 8-fold higher than for a conventional solution of resveratrol 44 . In our 526 case, the resveratrol bioavailability was 18-fold higher when loaded in zein 527 nanoparticles than when dissolved in the PEG400:water solution. Furthermore, zein 528 nanoparticles offering sustained and prolonged levels of resveratrol in plasma provided 529 a supplementary advantage when compared with other strategies. 530
Regarding the presence of the main metabolite (resveratrol-O-3-glucuronide 13 ) in the 531 plasma of animals, the levels of this compound (measured as AUC) were higher when 532 resveratrol was administered encapsulated in zein nanoparticles than when 533 administered in the conventional solution both by iv route (about 1.7 times) or orally 534 (around 3.3 times). This fact would be related with the slow release of the polyphenol 535 from the nanoparticles (where protected from degradation) and a prolonged residence 536 of nanoparticles in the gut mucosa due to their mucoadhesive properties. In other 537 words, by using nanoparticles, more resveratrol and during a longer period would reach 538 the circulation, counterbalancing the natural rapid metabolism of the drug. 539
Finally, we studied the anti-inflammatory activity of resveratrol when loaded in zein 540 nanoparticles. Several in vitro and in vivo studies suggest that resveratrol inhibits the 541 inflammatory response mediated by microbial stimuli 45 ; by inhibiting the transcription 542 factor NF-κB 10,11 . Therefore, we tested here the protective effect of encapsulated 543 resveratrol against the inoculation of LPS in mice. LPS is present exclusively on the 544 outer membrane of Gram negative bacteria, and consequently, it is one of the most 545 strong alarm signals for the innate immune system, inducing in animals a 546 pathophysiologic syndrome known as endotoxic shock. This syndrome is similar to 547 sepsis shock syndrome that progress on multiple organ failure 29, 46 , showing 548 piloerection, hypothermia, shivering, tachycardia and lethargy. These symptoms are 549 related with large amounts of released inflammatory mediators, such as TNF-α, NO 550 and prostaglandin E2 (PGE2), where TNF-α play a central role as being the first one to 551 be released 10 . In our experimental conditions, untreated mice challenged with LPS 552 (positive control) displayed the highest decrease in rectal temperature and the highest 553 TNF-α serum level. In contrast, Rsv-NP-Z administered daily during 7 days, were able 554 to diminish endotoxic symptoms like hypothermia or piloerection and increase the 555 movement of mice compared to those treated with resveratrol solution on daily basics 556 (Figure 6, Table 3 ). Moreover, for animals treated with Rsv-NP-Z, TNF-α levels were 557 lower than for controls; although the high variability of values abolished the statistical 558 significance. These results appear to indicate that the presence of sustained high 559 levels of resveratrol in plasma could be efficient to reduce the inflammatory mediators 560 in endotoxic shock induced by LPS. 561
In summary, zein nanoparticles appear to be interesting carriers for the oral delivery of 562 resveratrol. The polyphenol is released from this carrier by a combination of both 563 diffusion and erosion of the nanoparticle matrix, providing higher and more prolonged 564 plasma levels of resveratrol up to 48 h. Consequently, these nanocarriers significantly 565 increased the oral bioavailability of resveratrol reaching a value close to 50%. The oral 566 administration of these nanoparticles during one week to mice challenged with LPS 567 protected them from the inflammatory symptoms and mediators of the endotoxic shock. 568 
